Allakos Highlights Data Demonstrating Potential of AK002 to Rapidly Deplete Eosinophils at 2018 AAAAI/WAO Joint Congress -- Phase 1 data demonstrate AK002 rapidly depletes blood eosinophils after a single dose -- -- AK002 may provide an important new option in treating chronic allergic and inflammatory diseases such as...

Allakos Secures $100 Million In Series B Financing Proceeds will support advancement of AK002 in five disease areas  Lead clinical program evaluating AK002 in eosinophilic gastroenteritis, an inflammatory gastrointestinal disease  SAN CARLOS,...

Allakos Announces Additions to Senior Leadership Team Board of Directors appoints Robert Alexander as CEO and Adam Tomasi as COO & CFO Allakos plans to initiate a broad, multi-indication clinical program with AK002 in 2017 SAN CARLOS, Calif., Aug. ...